Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 390Carboplatin 344pembrolizumab 331Gemcitabine 331Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 287Bevacizumab 250Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 190fludarabine 178Oxaliplatin 178Pemetrexed 154Doxorubicin 152Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 128Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × voruciclib × Clear all
NCT03547115 2026-03-17

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

MEI Pharma, Inc.

Phase 1 Terminated
84 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡